Axsome Therapeutics Stock Performance
| AXSM Stock | USD 111.70 0.54 0.48% |
Axsome Therapeutics has a performance score of 6 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.63, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Axsome Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Axsome Therapeutics is expected to be smaller as well. Axsome Therapeutics right now shows a risk of 1.78%. Please confirm Axsome Therapeutics expected short fall, and the relationship between the maximum drawdown and rate of daily change , to decide if Axsome Therapeutics will be following its price patterns.
Risk-Adjusted Performance
Modest
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Axsome Therapeutics are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of very conflicting basic indicators, Axsome Therapeutics may actually be approaching a critical reversion point that can send shares even higher in August 2025. ...more
Actual Historical Performance (%)
One Day Return (0.48) | Five Day Return 2.5 | Year To Date Return 27.92 | Ten Year Return 1.2 K | All Time Return 1.2 K |
1 | Disposition of 3000 shares by Coleman Mark of Axsome Therapeutics at 107.491 subject to Rule 16b-3 | 05/20/2025 |
2 | 2 Soaring Stocks Wth More Upside Potential | 06/05/2025 |
3 | Axsome Therapeutics Announces Availability of SYMBRAVO for the Acute Treatment of Migraine with or without Aura in Adults | 06/10/2025 |
4 | Disposition of 7500 shares by Murdock Hunter R. of Axsome Therapeutics at 100.26 subject to Rule 16b-3 | 06/17/2025 |
5 | Disposition of 7500 shares by Murdock Hunter R. of Axsome Therapeutics at 100.9 subject to Rule 16b-3 | 06/18/2025 |
6 | Axsome Therapeutics Supports Alzheimers Awareness Initiatives AXSM Stock News | 06/20/2025 |
7 | Disposition of 6014 shares by Murdock Hunter R. of Axsome Therapeutics at 100.12 subject to Rule 16b-3 | 06/23/2025 |
8 | Peregrine Capital Management LLC Sells 27,466 Shares of Axsome Therapeutics, Inc. - MarketBeat | 07/01/2025 |
9 | Axsome Therapeutics Target Price Announced by Morgan Stanley AXSM Stock News | 07/03/2025 |
10 | Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health RD Day in New York City on July 21 | 07/07/2025 |
11 | Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4 AXSM Stock News | 07/09/2025 |
12 | Stocks Showing Improving Market Leadership Axsome Therapeutics Earns 85 RS Rating - MSN | 07/10/2025 |
| Begin Period Cash Flow | 386.2 M | |
| Total Cashflows From Investing Activities | -270 K |
Axsome Therapeutics Relative Risk vs. Return Landscape
If you would invest 10,300 in Axsome Therapeutics on April 21, 2025 and sell it today you would earn a total of 870.00 from holding Axsome Therapeutics or generate 8.45% return on investment over 90 days. Axsome Therapeutics is currently generating 0.1443% in daily expected returns and assumes 1.7775% risk (volatility on return distribution) over the 90 days horizon. In different words, 15% of stocks are less volatile than Axsome, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Axsome Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Axsome Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Axsome Therapeutics, and traders can use it to determine the average amount a Axsome Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0812
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | AXSM | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 1.78 actual daily | 15 85% of assets are more volatile |
Expected Return
| 0.14 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.08 actual daily | 6 94% of assets perform better |
Based on monthly moving average Axsome Therapeutics is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Axsome Therapeutics by adding it to a well-diversified portfolio.
Axsome Therapeutics Fundamentals Growth
Axsome Stock prices reflect investors' perceptions of the future prospects and financial health of Axsome Therapeutics, and Axsome Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Axsome Stock performance.
| Return On Equity | -2.82 | ||||
| Return On Asset | -0.26 | ||||
| Profit Margin | (0.64) % | ||||
| Operating Margin | (0.46) % | ||||
| Current Valuation | 5.41 B | ||||
| Shares Outstanding | 49.24 M | ||||
| Price To Earning | (3.34) X | ||||
| Price To Book | 103.37 X | ||||
| Price To Sales | 12.79 X | ||||
| Revenue | 385.69 M | ||||
| Gross Profit | 395.36 M | ||||
| EBITDA | (272.6 M) | ||||
| Net Income | (287.22 M) | ||||
| Cash And Equivalents | 73.39 M | ||||
| Cash Per Share | 1.82 X | ||||
| Total Debt | 192.96 M | ||||
| Debt To Equity | 6.20 % | ||||
| Current Ratio | 2.44 X | ||||
| Book Value Per Share | 1.08 X | ||||
| Cash Flow From Operations | (128.41 M) | ||||
| Earnings Per Share | (5.77) X | ||||
| Market Capitalization | 5.53 B | ||||
| Total Asset | 568.5 M | ||||
| Retained Earnings | (1.12 B) | ||||
| Working Capital | 254.96 M | ||||
| Current Asset | 34.76 M | ||||
| Current Liabilities | 6.74 M | ||||
About Axsome Therapeutics Performance
By examining Axsome Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Axsome Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Axsome Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 172.42 | 252.16 | |
| Return On Tangible Assets | (0.56) | (0.59) | |
| Return On Capital Employed | (0.83) | (0.87) | |
| Return On Assets | (0.51) | (0.53) | |
| Return On Equity | (5.04) | (4.79) |
Things to note about Axsome Therapeutics performance evaluation
Checking the ongoing alerts about Axsome Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Axsome Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the previous year's revenue of 385.69 M. Net Loss for the year was (287.22 M) with profit before overhead, payroll, taxes, and interest of 395.36 M. | |
| Axsome Therapeutics currently holds about 73.39 M in cash with (128.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.82. | |
| Axsome Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 77.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Stocks Showing Improving Market Leadership Axsome Therapeutics Earns 85 RS Rating - MSN |
- Analyzing Axsome Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Axsome Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Axsome Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Axsome Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Axsome Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Axsome Therapeutics' stock. These opinions can provide insight into Axsome Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axsome Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.77) | Revenue Per Share | Quarterly Revenue Growth 0.62 | Return On Assets | Return On Equity |
The market value of Axsome Therapeutics is measured differently than its book value, which is the value of Axsome that is recorded on the company's balance sheet. Investors also form their own opinion of Axsome Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Axsome Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axsome Therapeutics' market value can be influenced by many factors that don't directly affect Axsome Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Axsome Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Axsome Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axsome Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.